Discover
MNKD
MannKind Corporation
3.54
2 x 2.93
2 x 5.03
bid
ask
-
0.04
1.12%
2 @ 04:00 AM
3.49 -0.05 (1.49%)
| Ytd | -37.57% | |
| 1y | -36.90% |
3.50
day range
3.62
2.23
52 week range
6.51
| Open | 3.62 | Prev Close | 3.58 | Low | 3.50 | High | 3.62 | Mkt Cap | 1.14B |
| Vol | 5.51M | Avg Vol | 4.26M | EPS | -0.15 | P/E | N/A | Forward P/E | 27.76 |
| Beta | 1.10 | Short Ratio | 6.39 | Inst. Own | 57.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 3.95 | 200-d Avg | 4.09 | 1yr Est | 7.97 |
MNKD News
marketbeat.com
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development prioritie
benzinga.com
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overwei
benzinga.com
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule
MannKind licenses Technosphere GLP-1 tech to Rose Pharma for weight management development.
benzinga.com
MannKind And Rose Pharma Enter Into Worldwide Licensing And Collaboration Agreement To Develop ROSE-
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind
benzinga.com
MannKind Files Prospectus For Resale By Selling Stockholders Of Up to 12,853,470 Shares, Including 2
Up to 12,853,470 SharesCommon StockThis prospectus supplement relates to the offer and resale by the